Cenkos Securities Ltd restated their buy rating on shares of Cello Group plc (LON:CLL) in a research report released on Wednesday morning.

Separately, Peel Hunt restated a buy rating and issued a GBX 130 ($1.70) price objective on shares of Cello Group plc in a research note on Thursday, June 23rd.

Cello Group plc (LON:CLL) opened at 107.60 on Wednesday. Cello Group plc has a 12-month low of GBX 77.10 and a 12-month high of GBX 115.00. The stock has a 50 day moving average price of GBX 104.04 and a 200 day moving average price of GBX 97.59. The stock’s market cap is GBX 93.55 million.

The business also recently disclosed a dividend, which will be paid on Friday, November 4th. Stockholders of record on Thursday, October 6th will be paid a GBX 1 ($0.01) dividend. The ex-dividend date of this dividend is Thursday, October 6th. This represents a dividend yield of 0.94%.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.